NASDAQ:IMMX
Immix Biopharma, Inc.
Immix Biopharma, Inc. reported net income of −$29.4M in fiscal 2025. Free cash flow was −$24.7M, and the diluted share count rose 16.5%.Summary generated from Immix Biopharma, Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−55.0%
Debt / equityn/a
Free cash flow−$24.7M
FCF marginn/a
Share count change+16.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −1 | −8 | −16 | −23 | −30 |
| Net income | −24 | −8 | −15 | −22 | −29 |
| Free cash flow | −2 | n/a | −11 | −16 | −25 |
Recent filings
- 8-KOther events
Sep 30, 2026 - 8-KRegulation FD disclosure
Sep 29, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 7, 2026 - 8-KOther events
Jul 20, 2026 - 8-KResults of a shareholder vote
May 29, 2026 - 4Insider transaction report
May 29, 2026 - 4Insider transaction report
May 29, 2026 - 8-KOther events
May 21, 2026